Psychopharmacology

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.

What are the risks and benefits of antipsychotic polypharmacy for the treatment of schizophrenia?

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Here are highlights from the week in Psychiatric Times.

Polypharmacy is often overlooked in patients with significant traumatic brain injury. How can you best manage medication in these patients?

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The company has announced plans to submit the NDA in the first half of 2025.

“The findings emphasize the importance of monitoring the use of psychotropic combinations, particularly among vulnerable populations.”

Here are highlights from the week in Psychiatric Times.

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.

Here’s how an integrated psychosocial and pharmacologic approach can enhance SUD treatment.

Here are highlights from the last day of this year’s APA Annual Meeting.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster covered a literature review on the relationship between stimulant use and failure to thrive in pediatric patients with ADHD.

Explore treatment resistance at the 2024 APA Annual Meeting!

Here are some updates from the world of psychiatry throughout the month of April.

Here are highlights from the week in Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”